综述:乙型肝炎核心相关抗原(HBcrAg):慢性乙型肝炎病毒感染的新兴标志物
本文综述了乙型肝炎核心相关抗原(HBcrAg)的病毒学特点及临床应用。截至2017年3月检索PubMed等文献发现,HBcrAg与肝内cccDNA、肝内总HBV DNA、血清HBV DNA相关性好,与HBsAg相关性较弱;在血清HBV DNA不可测或HBsAg消失时仍可检出。HBcrAg有助于区分HBeAg阴性慢性肝炎与慢性感染、预测HBeAg血清学转换、核苷(酸)类似物持续应答、免疫抑制下隐匿性HBV感染再激活风险及HCC发生和术后复发风险。
要点
- HBcrAg与肝内cccDNA、肝内总HBV DNA及血清HBV DNA相关性好,与HBsAg相关性较弱。
- 血清HBV DNA不可测或HBsAg消失时,HBcrAg仍可检出。
- HBcrAg有助于区分HBeAg阴性慢性肝炎与慢性感染,并预测HBeAg血清学转换等。
核心结论
- HBcrAg是cccDNA的潜在替代标志物,可能很快成为疾病监测、预测治疗应答和疾病结局的有用标志物。
研究设计与样本
- 综述:检索截至2017年3月PubMed期刊列表及主要国际会议摘要中关键词为「HBcrAg」或「hepatitis B core-related antigen」的文献,基于现有理论及作者经验对入选研究进行比较和总结。
主要发现
- HBcrAg与肝内cccDNA、肝内总HBV DNA、血清HBV DNA相关性好,与HBsAg相关性较弱。
- 在血清HBV DNA不可测或HBsAg消失的情况下,HBcrAg仍可检出。
- HBcrAg有助于区分HBeAg阴性慢性肝炎与HBeAg阴性慢性感染。
- HBcrAg可预测自发性或治疗诱导的HBeAg血清学转换、核苷(酸)类似物持续应答、免疫抑制治疗下隐匿性HBV感染的再激活风险、HCC发生风险及术后HCC复发风险。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic hepatitis B (CHB) cannot be completely eradicated due to the presence of covalently closed circular DNA (cccDNA) in the nuclei of infected hepatocytes. While quantification of intrahepatic cccDNA requires liver biopsies, serological markers can be non-invasive alternatives to reflect intrahepatic viral replicative activity. Recently, hepatitis B core-related antigen (HBcrAg) has been advocated as a novel serum marker for disease monitoring and prognostication of CHB. AIM: To examine the virological aspect and clinical application of HBcrAg with respect to the natural history and treatment of CHB. METHODS: We reviewed all papers published in the PubMed journal list and abstracts from major international meetings that included the keyword "HBcrAg" or "hepatitis B core-related antigen" until March 2017. Selected studies were compared and summarised on the basis of existing theories, as well as the authors' experience. RESULTS: HBcrAg exhibited good correlation with intrahepatic (ih) cccDNA, ih total hepatitis B virus (HBV) DNA, serum HBV DNA and to a lesser extent HBV surface antigen (HBsAg). In situations where serum HBV DNA levels become undetectable or HBsAg loss is achieved, HBcrAg can still be detectable. This marker is helpful in differentiation of HBeAg-negative chronic hepatitis from HBeAg-negative chronic infection, predicting spontaneous or treatment-induced HBeAg seroconversion, sustained response to nucleos(t)ide analogue (NA), risk of HBV reactivation in occult HBV infection under immunosuppressive therapies, and risk of hepatocellular carcinoma (HCC) development as well as post-operative HCC recurrence. CONCLUSIONS: HBcrAg is a potential surrogate marker of cccDNA. It may soon become a useful marker for disease monitoring, predicting treatment response and disease outcome of chronic hepatitis B.
引用
- Mak LY, Wong DK, Cheung KS, et al. Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection. Aliment Pharmacol Ther. 2017. PMID: 29035003. doi:10.1111/apt.14376
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。